Mallinckrodt PLC
MNK
Real-time BATS EXCHANGE - 07/19 09:23:00 pm
22.015USD
+0.92%
Prev.21.8200
Open21.9000
High22.1800
Low21.4400
Volume1 580 197
Financials
Sales 2018 2 467 M
EBIT 2018 962 M
R. net 2018 137 M
Debt 2018 5 557 M
Rend. 2018 -
P/E ratio 2018 13,62
P/E ratio 2019 11,70
EV / Sales 2018 2,98x
EV / Sales 2019 2,58x
Capitalization 1 795 M
Company
Mallinckrodt Plc operates as a global specialty pharmaceuticals company.It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents.It operates through the Specialty Brands and Specialty Generics segments.The Specialty...
Sector :
Specialty & Advanced Pharmaceuticals
Calendar :
2018-08-07 Earnings Release
Trading Rating :
Investor Rating :
Latest news
07/11MALLINCKRODT : New Health Economic Data on Mallinckrodt's OFIRMEV Injection Published in Journal of Knee Surgery
AQ
07/11Free Stock Performance Review on Mallinckrodt and Three Additional Generic Drugs Stocks
AC
07/09MALLINCKRODT : New Health Economic Data on Mallinckrodt's OFIRMEV® (Acetaminophen) Injection Published in Journal of Knee Surgery
PR
07/05MALLINCKRODT : Reports Interim Findings Of H.P. Acthar® Gel Repository Corticotropin Injection Studies
AQ
07/03MALLINCKRODT : Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar Gel Achieves its Enrollment Target
AQ
06/30MALLINCKRODT : Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar Gel (Repository Corticotropin Injection) Achieves its Enrollment Target
AQ
06/30MALLINCKRODT : rheumatoid arthritis study for H.P. Acthar Gel
AQ
06/28MALLINCKRODT : Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar® Gel (Repository Corticotropin Injection) Achieves its Enrollment Target
PR
Technical analysis trends
Short TermMid-TermLong Term
TrendBullishBullishBearish
Resistance23,124,122,6
Spread/Res.-4,5%-8,2%-2,1%
Spread/Supp.9,4%29%84%
Support20,217,112,0